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H19/let-7/LIN28 reciprocal negative regulatory circuit
promotes breast cancer stem cell maintenance
Fei Peng1,9, Ting-Ting Li1,9, Kai-Li Wang1,9, Guo-Qing Xiao2, Ju-Hong Wang3, Hai-Dong Zhao2, Zhi-Jie Kang1,4, Wen-Jun Fan1,
Li-Li Zhu5, Mei Li3, Bai Cui1, Fei-Meng Zheng1,6, Hong-Jiang Wang7, Eric W-F Lam8, Bo Wang*,6, Jie Xu*,1 and Quentin Liu*,1
Long noncoding RNA-H19 (H19), an imprinted oncofetal gene, has a central role in carcinogenesis. Hitherto, the mechanism by
which H19 regulates cancer stem cells, remains elusive. Here we show that breast cancer stem cells (BCSCs) express high levels of
H19, and ectopic overexpression of H19 significantly promotes breast cancer cell clonogenicity, migration and mammosphere-
forming ability. Conversely, silencing of H19 represses these BCSC properties. In concordance, knockdown of H19 markedly
inhibits tumor growth and suppresses tumorigenesis in nude mice. Mechanistically, we found that H19 functions as a competing
endogenous RNA to sponge miRNA let-7, leading to an increase in expression of a let-7 target, the core pluripotency factor LIN28,
which is enriched in BCSC populations and breast patient samples. Intriguingly, this gain of LIN28 expression can also feedback to
reverse the H19 loss-mediated suppression of BCSC properties. Our data also reveal that LIN28 blocks mature let-7 production
and, thereby, de-represses H19 expression in breast cancer cells. Appropriately, H19 and LIN28 expression exhibits strong
correlations in primary breast carcinomas. Collectively, these findings reveal that lncRNA H19, miRNA let-7 and transcriptional
factor LIN28 form a double-negative feedback loop, which has a critical role in the maintenance of BCSCs. Consequently,
disrupting this pathway provides a novel therapeutic strategy for breast cancer.
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Breast cancer is the leading cause of cancer-related death
among females worldwide.1,2 Although early diagnosis and
more effective treatment strategies have diminished the
mortality rates in recent years,3–5 the development of
recurrence,metastasis and chemoresistance is, inmost cases,
still inevitable.6 Breast cancer stem cells (BCSCs) have been
shown to exhibit unique characteristics, including enhanced
self-renewal, dedifferentiation and resistance to chemotherapy
or radiotherapy, all of which are believed to contribute to the
development and overall aggressiveness of the recurrent or
metastatic lesions.7–9 The initial evidence for the existence of
cancer stem cells (CSCs) in breast cancer reveals that only the
minority of breast cancer cells with a CD44+/CD24− /low/ESA+
phenotype have the ability to form new tumors in NOD/SCID
mice.10 In addition, theCD44+/CD24− phenotype is enriched in
basal-like breast tumors11 and related to triple-negative state in
breast cancer.12 BCSCs also present high aldehyde dehydro-
genase 1 (ALDH1) expression and enhance ‘side population’
(SP) cells that efflux the Hoechst dye via ABCG2 (a key factor
contributing to drug resistance in cancers).13,14 Furthermore,
BCSCs possess the property to form mammospheres, which
are thought to be enriched mammary stem cells.15 Therefore,
eliminating BCSCs provide a therapeutic avenue for
overcoming chemoresistance, metastasis and relapse in
breast cancer patients.16
Long noncoding RNA H19 is maternally imprinted and
locates close to the telomeric region of chromosome
11p15.5.17 This gene is activated in murine extraembryonic
cell types at the time of implantation, but is subsequently
expressed in all of the mid-gestation embryo cells excluding
most of the developing central and peripheral nervous
systems. After birth, the expression of this gene ceases or
markedly decreases in all tissues.18 Maternal allele-specific
deletion of the H19 differential methylated region maintains
hematopoietic stem cell repopulating ability through a
miR-675-Igf1 signaling circuit.19 A critical trans-regulatory
function in skeletal muscle differentiation and regeneration is
mediated by the microRNAs (miR-675-3p and miR-675-5p)
encoded within H19.20 Moreover, H19 serves as a molecular
sponge to regulate the bioavailability of tumor suppressor
miRNA let-7 during the process of endometrial cancer
metastasis.21 Although recent findings have indicated
that H19 has important roles in regulating tumorigenicity22
and stemness of glioblastoma,23 little is known about the
mechanism by which H19 controls cancer stem cell
maintenance.
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A highly conserved RNA-binding protein LIN28 is a member
of reprogramming factors acted in concert with KLF4, SOX2
and NANOG, to induce pluripotency in adult human fibroblast
cells.24,25 Accumulating evidence has indicated that LIN28 is
overexpressed in advanced human malignancies and has a
key role in the maintenance of CSCs.26,27 LIN28A binds to
conserved terminal loop of pre-let-7 elements and induce
terminal uridylation (addition of uridine nucleotides) of pre-let-
7 via recruitment of Zcchc11, a terminal uridylyl transferase
(TUTase) and TUT4.28 After that, DICER is unable to cleave
uridylated pre-let-7 transcript, inhibiting the production of
mature let-7 miRNAs (a key ‘keeper’ of the differentiated state
of embryonic stem cells).29 Thus, blockage of let-7 production
and subsequent de-repression of let-7 miRNA target
genes (RAS, MYC and HMGA2) by LIN28 has an essential
function in CSC maintenance.30,31 Moreover, LIN28 post-
transcriptionally upregulates LGR5 and PROM1 through let-7-
independentmechanism, promoting colon cancer progression
and metastasis.26
Here we demonstrate that H19 expression is enriched in
BCSC subpopulations and breast tumor samples. As a
competing endogenous RNA (ceRNA), H19 increases LIN28
expression by blocking the bioactivity of let-7, an upstream
repressor of H19. In addition, LIN28 induction can further
reduce let-7 expression in a feedback mechanism. Taken
together, our results suggest that H19/let-7/LIN28 forms a
double-negative reciprocal circuitry to facilitate BCSC
maintenance.
Results
H19 is highly expressed in human breast tumors and
BCSC subpopulations. To investigate the relationship
between H19 and BCSCs, we assessed the expression of
H19 in breast cancer tissues and breast cancer cells. In
breast cancer samples, H19 levels were significantly higher in
cancerous tissues compared with the adjacent normal
tissues (Figure 1a, Po0.01; Figure 1b). In addition, the
Kaplan–Meier survival analysis demonstrated that high H19
level was a strong indicator for an inferior overall survival in
breast cancer patient samples (Figure 1c). Furthermore,
breast tumors were induced in mice (Brca1−/− p53 +/− ), and
RT-qPCR assay showed that H19 was significantly upregu-
lated in tumors compared with normal mammary glands
(Figure 1d). Consistently, H19 expression was detected at
higher levels in breast cancer cells than in breast epithelial
cells and stemness-related factors OCT4, SOX2 and NANOG
were expressed at higher levels in MDA-MB-231 cells
compared with MCF-10A cells (Figure 1e and
Supplementary Figure 1A). We next sorted ALDH1+
(Figure 1f, left) and SP cells (Figure 1g, left) from MDA-
MB-231 cells by fluorescence-activated cell sorting (FACS) to
enrich BCSC subpopulations. Notably, the expression of H19
was significantly enhanced in ALDH1+ (Figure 1f, right,
Po0.001) and SP cells (Figure 1g, right, Po0.001).
POU5F1, SOX2 and NANOG were highly expressed in
BCSC-enriched populations compared with non-enriched
cells (Supplementary Figure 1B). Moreover, the expression
of H19 was also elevated in sphere-forming (Supplementary
Figure 1C) and three-dimensional (3D) culture (Supplementary
Figure 1E) cells. Similarly, the expression of POU5F1, SOX2
and NANOG in sphere-forming (Supplementary Figure 1D) and
3D culture (Supplementary Figure 1F) cells were increased to
determine the BCSC enrichment. These results demonstrate
that BCSCs express higher levels of H19.
H19 is required for the maintenance of BCSC character-
istics. To assess the role of H19 in the regulation of BCSCs
properties, we established stable H19-overexpressing MDA-
MB-231 cells and confirmed the enforced expression of H19
by RT-qPCR (Figure 2a). Then, we performed colony
formation, transwell migration and sphere formation assays.
Colony numbers were distinctly increased in H19-overexpres-
sing MDA-MB-231 cells compared with controls (Figure 2b,
Po0.001). Number of migration cells was also markedly
elevated in H19-overexpressing cells (Figure 2c, Po0.001). In
addition, sphere formation capacity was significantly
enhanced upon H19 overexpression (Figure 2d, left). Both
size and number of spheres were markedly elevated in H19-
overexpressing cells (Figure 2d, middle, Po0.001; Figure 2d,
right, Po0.01). Moreover, overexpressing H19 in another
breast cancer cell line SK-BR-3 (Supplementary Figure 2A),
also resulted in similar increases in self-renewal properties
(Supplementary Figures 2B–D). In contrast, when H19 was
knocked down by short hairpin RNAs (shRNAs) in MDA-
MB-231 and SK-BR-3 cells (Figure 2e; Supplementary
Figure 2E), there was a significant reduction in clonogenicity,
migration and sphere-forming ability in MDA-MB-231
(Figures 2f–h) and SK-BR-3 cells (Supplementary Figures
2F–H). Interestingly, overexpression or knockdown of H19
displayed no effects on cell proliferation in MDA-MB-231
(Supplementary Figures 3A and B) and SK-BR-3 cells
(Supplementary Figures 3C and D). Together, these data
showed that H19 is crucial for the maintenance of BCSC
properties in vitro.
H19 is essential for tumorigenesis and tumor growth
in vivo. As continuous tumor growth could be sustained by
BCSCs, we performed serial transplantation in nude mice to
investigate the in vivo role of H19 in the regulation of BCSC
maintenance. In the first tumor transplantation, either MDA-
MB-231-shCtrl (NTC) or MDA-MB-231-shH19 (shH19) cells
were subcutaneously transplanted into nude mice (n= 5). As
shown in Figure 3a, the mice injected with shH19 cells
formed apparently smaller tumor mass than the mice
injected with NTC cells, indicating that H19 was critical for
tumor growth. Importantly, the cells isolated from shH19
tumor xenografts, with a 77.6% knockdown efficiency
(Supplementary Figure 4A), displayed diminished clonogeni-
city, migration and sphere-forming ability compared with the
cells from NTC tumor xenografts (Supplementary Figures
4B–D). Furthermore, H19 depletion significantly repressed
the second limited dilution tumor transplantation. As shown in
Figure 3b, not only the tumor volumes but also the tumor
formation efficiencies decreased in the shH19 tumor xeno-
grafts compared with the NTC tumor xenografts. When
shH19 cells (1 × 102) were injected into nude mice (n=5),
these cells failed to generate an observable tumor mass. In
contrast, the same number of NTC cells generated tumor
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Figure 1 LncRNA-H19 expression is assessed in clinical breast cancer specimens and cancer cell lines. (a) Analysis of H19 expression in breast cancerous tissues and
adjacent normal tissues (n= 20). The relative H19mRNA level was normalized to ACTB. The statistical differences were analyzed using the paired t-test. (b) In situ analysis with
a DIG-labeled H19 probe in breast cancerous tissue and adjacent normal tissues. The scale bar represents 100 μm. (c) Kaplan–Meier survival analysis was performed to
investigate the implication of H19 level on patient overall survival (n= 20). (d) Mice harboring BLG-Cre; Brca1F22–24/F22–24; p53 +/− were established by two rounds of pregnancy
and then tumors developed were collected (n= 3). H19 expression was further verified in tumor and mammary tissues by RT-qPCR assay. (e) The in situ expression of H19 RNA
(red) was detected by FISH assay. The red fluorescent signal is from the H19 RNA probe, and the blue fluorescent signal is from nuclear DNA counterstained with DAPI. The scale
bar represents 20 μm. (f and g) Detections of H19 expression in the ALDH1-positive (ALDH1+) subpopulation (f) and side population (SP) cells (g) are showed by dot plots by
FACS and the relative expression levels in MDA-MB-231 cells. Data are represented as mean±S.D. **Po0.01 and ***Po0.001, n= 3
H19/let-7/LIN28 feedback loop maintains BCSCs
F Peng et al
3
Cell Death and Disease
Figure 2 LncRNA-H19 is involved in the maintenance of CSC characteristics in breast cancer cells. (a) Ectopic expression of H19 mRNA expression was confirmed by
RT-qPCR after lentivirus infection in MDA-MB-231 cells. (b) Ectopic overexpression of H19 enhanced clonogenic growth in vitro. Representative images of colonies were
presented (left) and colony numbers were counted after culture for 12 days (right). Data are represented as mean±S.D. ***Po0.001, n= 3. (c) Cell migration was analyzed in
H19 overexpression and control groups. Stained images of invaded cells are presented (left) and migrated numbers are mean±S.D. (n= 3), ***Po0.001 (right).
(d) Mammosphere formation was increased by H19 overexpression. Representative images were presented (left), and the size and numbers of mammospheres were counted
(right). Data were shown as mean± S.D. from three independent experiments, **Po0.01 and ***Po0.001, respectively. (e) The interfering efficiency of the lentivirus encoding
H19-targeting shRNAs (shH19) were confirmed by RT-qPCR, compared with negative control lentivirus (NTC). (f–h) Knockdown of H19 reduced breast cancer cells clonogenicity
(f), migration (g) and mammosphere-forming ability (h). Data were shown as mean±S.D. from three independent experiments, **Po0.01 and ***Po0.001, respectively
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mass in four out of five mice. Furthermore, the clonogenicity,
migration and sphere-forming ability remained substantially
lower in the cells isolated from the shH19 tumor xenografts of
the second transplantation, with 66.8% knockdown efficiency
of H19 (Figure 3c) in comparison with the cells from the NTC
tumor xenografts (Figures 3d–f). These data strongly
supported that H19 has a critical role in the maintenance of
BCSCs in vivo.
H19 functions as a molecular sponge for let-7 miRNA in
breast cancer cells. To explore the molecular mechanism
whereby H19 regulates BCSCs, we first examined the
Figure 3 Endogenous LncRNA-H19 is required for CSCs maintenance in vivo. (a) H19 depletion attenuated xenograft tumor growth after the first tumor transplantation. MDA-
MB-231 cells were infected with lentivirus shH19-3 or NTC; cells were subcutaneously injected into nude mice, respectively. Representative images of subcutaneous tumors taken
6 weeks post inoculation (left) and the tumor growth curves were presented (right). Data are presented as the mean± S.D. (n= 5; *Po0.05, **Po0.01 and ***Po0.001). (b) H19
knockdown significantly repressed in vivo tumor formation after second serial tumor transplantation. Shown were representative images of subcutaneous tumors collected at end
point (left) and summary of tumor xenografts formation of different groups in nude mice (right). (c) The knockdown efficiency ofH19 in the second tumor xenografts were detected by
RT-qRCR. Error bars represent mean± S.D. of triplicates. (d–f) The cancer cells isolated from H19 knockdown tumor xenografts displayed the reduced clonogenicity (d), migration
(e) and mammosphere-forming (f) abilities. Data were shown as mean± S.D. from three independent experiments, **Po0.01 and ***Po0.001, respectively
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expression level and location of H19 in breast cancer
cells. As shown in Figure 4a (MDA-MB-231 cells) and
Supplementary Figure 5A (SK-BR-3 cells), H19 expressed
at higher levels in the cytoplasm than in the nucleus
(Po0.001). This result was further confirmed by FISH assay,
which showed that H19 transcripts were abundant in the
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cytoplasm of MDA-MB-231 (Figure 4b) and SK-BR-3 cells
(Supplementary Figure 5B). These findings suggested that
H19 interacts with miRNAs in the cytoplasm and functions as
endogenous sponges for miRNAs. To test this conjecture, we
next performed RNA immunoprecipitation (RIP) analysis with
antibodies against AGO2 using extracts from MDA-MB-231
cells. The results showed that H19 was elevated in AGO2-
containing miRNPs compared with control IgG immunopre-
cipitates (Figure 4c, left, Po0.01). Western blotting con-
firmed that AGO2 was expressed in the input and the pulled
down complexes (Figure 4c, right). These data showed that
H19 is recruited to AGO2-related RNA-induced silencing
complexes and functionally interacted with miRNAs in breast
cancer cells.
Furthermore, let-7 mimics (mlet-7) substantially repressed
the luciferase activities of the psiCHECK2-let-7 4 × and
psiCHECK2-H19 (Po0.001) reporters, which harbors four
and two copies of let-7-binding sites, respectively. By contrary,
psiCHECK2-H19D, with let-7-binding sites deletion, no longer
responded to mlet-7 (Figure 4d). We further generated H19-
overexpressing plasmidswith either wild-type (WT) or mutated
(Mut) let-7-binding sites. The psiCHECK2-let-7 4 × reporter
was co-transfected with increasing amounts of WTH19 or Mut
H19 (sponge) intoMDA-MB-231 cells. The results showed that
the relative let-7 reporter luciferase activity was increased in
response to WT H19 in a dose-dependent manner but
remained unchanged with the Mut H19 plasmids (Figure 4e).
Notably, although the expression levels of let-7a and let-7b
were unaltered when H19 was overexpressed in MDA-
MB-231 cells (Figure 4f), the protein levels of DICER and
RAS targeted by let-7 were increased (Figure 4g). Similarly,
let-7a and let-7b displayed no significant changes in expres-
sion levels when H19 was silenced by small interfering RNAs
(siRNAs; Figure 4h), whereas the levels of DICER
and RAS were markedly decreased in H19 knockdown cells
(Figure 4i). Consistently, similar results were also observed for
SK-BR-3 cells upon H19 overexpression and depletion
(Supplementary Figures 5C and D). Taken together,
these findings evidently suggest that H19 acts as a miRNA
sponge to restrict the biological function of let-7 in breast
cancer cells.
H19 elevates LIN28 expression through a let-7-dependent
mechanism. To identify the potential downstream targets of
H19 and let-7 involved in BCSC maintenance, we first
examined the expression levels of a panel of core pluripo-
tency factors upon H19 overexpression in breast cancer cells.
Interestingly, overexpression of H19 resulted in a substantial
increase of LIN28 protein level in MDA-MB-231 and SK-BR-3
cells (Figure 5a). As LIN28 was a validated target of let-7, we
examined whether LIN28 was regulated by the H19/let-7 axis
in breast cancer cells. LIN28 expression was remarkably
reduced following H19 depletion by siRNAs in two breast
cancer cells (Figure 5b). In addition, both the levels of
LIN28 mRNA (Supplementary Figure 6A) and protein
(Supplementary Figure 6B) decreased in the presence of
mlet-7 and increased in the presence of let-7 inhibitors
(ilet-7). Furthermore, the 3′UTR sequence of LIN28 was
fused to the luciferase-coding region (psiCHECK2-LIN28,
Supplementary Figure 6C) and transfected into MDA-MB-231
cells together with mlet-7 in parallel with the negative control
(NC). The results showed that mlet-7 significantly repressed
the relative luciferase activity of reporter psiCHECK2-LIN28
(Figure 5c, Po0.01). However, when we co-transfected
psiCHECK2-LIN28 (sensor) with increasing amounts of WT
H19 (sponge) into MDA-MB-231 cells, the relative luciferase
activity was promoted in response to WT H19, but Mut H19,
in a dose-dependent manner (Figure 5d). The effect of H19/
let-7 axis in the regulation of LIN28 expression was further
investigated by rescue assay shown in Figure 5e. The results
revealed that the expression of LIN28 decreased in the
presence of mlet-7, whereas it increased in the presence of
WT H19. Notably, WT H19 was able to restore synthesis of
LIN28 protein, even in the presence of mlet-7. On the
contrary, these effects were blocked when Mut H19 were
used. To test whether BCSC maintenance by H19 is
dependent on LIN28, LIN28 stably overexpressing cells were
established from H19 knockdown MDA-MB-231 (shH19) cells
(Supplementary Figure 6D). H19 knockdown resulted in a
decrease in sphere formation capacity in MDA-MB-231 cells,
whereas co-overexpression of LIN28 reversed this reduction
(Figure 5f). Similar rescues were found for colony
formation and transwell migration when LIN28 was over-
expressed (Supplementary Figures 6E and F). Indeed,
protein level of LIN28 was higher in MDA-MB-231 cells
compared with the non-cancerous MCF-10A cells
(Supplementary Figure 6G). Consistently, LIN28 expression
was also increased in ALDH1+ cells and SP cells
(Supplementary Figure 6H, Po0.001). As shown in
Figures 5g and h, the mRNA and protein levels of LIN28
were significantly higher in breast cancer tissues than
corresponding adjacent non-cancerous tissues (Po0.01). In
addition, H19 and LIN28 also displayed a strong
correlation in breast patient tumors (Figure 5i, Po0.001).
Figure 4 LncRNA-H19 acts as an endogenous miRNA let-7 sponge in breast cancer cells. (a) Comparison of the expression of H19 in cytoplasm and in nucleus by
RT-qPCR. Data are represented as mean±S.D. ***Po0.001, n= 3. (b) Shown was the representative image of the in situ location of H19 transcripts in MDA-MB-231 cells. The
scale bar represents 20 μm (left) and 10 μm (right). (c) Immunoprecipitation using anti-AGO2 antibody (lane 3) or IgG (lane 2) followed by western blot analysis using a mouse
monoclonal anti-AGO2 (right). Co-IP with rabbit anti-AGO2 antibody or preimmune IgG from extracts of MDA-MB-231 cells. H19 RNA levels in immunoprecipitates were
determined by RT-qPCR (left). Data were shown as mean± S.D. from three independent experiments, **Po0.01. (d) The target validation using luciferase reporters; the
indicated constructs were each transfected into MDA-MB-231 cells together with negative control miRNA (NC) or let-7 mimics (mlet-7) at a final concentration of 48 nM. Numbers
are mean± S.D. (n= 3, ***Po0.001). (e) Let-7 sensor (psiCHECK2-let-7 4x) was transfected into MDA-MB-231 cells, together with 0, 20, 40 or 80 ng of sponge plasmid wide
type H19 (WT) or mutant H19 (Mut). Numbers are mean±S.D. (n= 3, *Po0.05, **Po0.01). (f) Empty vector (EV) or full-length H19 (WT) was transfected into MDA-MB-231
cells. The relative H19 mRNA level was normalized to ACTB and let-7a/7b miRNA levels were normalized against those of U6B. Numbers are mean±S.D. (n= 3). (g) The
protein levels of let-7 targets DICER and RAS were confirmed by western blot. (h) MDA-MB-231 cells were transfected with siRNA targeting H19 (siH19) or negative control RNA
(siNC), H19 expression levels and let-7a/7b miRNA levels were evaluated by RT-qPCR, and (i) the protein levels of let-7 targets were detected by western blot
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Together, these results suggest that H19 acts as a ceRNA to
inhibit let-7 function, leading to de-repression of LIN28 that is
crucial for the maintenance of BCSCs.
LIN28 promotes H19 expression by suppressing let-7
production. The co-overexpression of H19 and LIN28 led us
to ask whether H19 is also upregulated by LIN28. Ectopic
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overexpression (Figure 6a) and transient knockdown
(Figure 6c) of LIN28 remarkably increased (Figure 6b) and
reduced (Figure 6d) H19 expression, respectively. Similar
results were observed in SK-BR-3 cells (Supplementary
Figures 7A–D). These results indicated a reciprocal positive
regulation between LIN28 and H19. In agreement with the
fact that LIN28 is a post-transcriptional repressor of let-7, the
let-7a and let-7b miRNA levels were markedly decreased
by overexpression of LIN28 (Figure 6e; Supplementary
Figure 7E). Furthermore, mlet-7 significantly repressed the
expression of H19, ilet-7 remarkably enhanced H19 expres-
sion in both MDA-MB-231 (Figure 6f) and SK-BR-3 cells
(Supplementary Figure 7F). These data suggest that H19 is
reciprocally inhibited by its target let-7, and that this negative
feedback loop can be disrupted by LIN28 through its ability to
repress let-7 expression.
Next, we analyzed H19 expression following LIN28 knock-
down in combination with ilet-7 overexpression. As shown in
Figure 6g, ilet-7 increased H19 expression (Po0.05) and
LIN28 knockdown caused a downregulation ofH19 (Po0.05),
whereas co-transfection of ilet-7 relieved this H19 down-
regulation caused by LIN28 knockdown (Po0.05). Similar
results were identified in SK-BR-3 cells (Supplementary
Figure 7G). As let-7 is suppressed by both H19 and LIN28 in
breast cancer cells, we analyzed let-7 expression in three
paired breast cancer patient samples. Let-7a and let-7b were
substantially downregulated in breast cancer patient tissues
compared with the corresponding adjacent non-cancerous
tissues (Figures 6h and i). As cancer stem cells tend to
cause metastasis in breast tumor, we further examined the
expression of H19, LIN28 and let-7 in metastatic and
non-metastic mammary tumors from twenty tumor tissues
stratified on clinical progression. Intriguingly, the results
showed that H19 and LIN28 levels were highly expressed in
metastasis tumors, whereas let-7a and let-7b levels were
much lower in metastasis tumors than non-metastasis tumors
(Supplementary Figures 7H-J). In conclusion, our study
establishes that H19/let-7/LIN28 form a double-negative
feedback circuitry to regulate BCSC maintenance (Figure 6j).
Discussion
In present study, we demonstrate that H19-let-7-LIN28 exhibit
a double-negative feedback loop in regulation of BCSC
maintenance. In agreement, H19 is significantly elevated in
breast tumors and BCSC-enriched populations (Figure 1).
Moreover, H19 has a critical role in promoting BCSC proper-
ties and tumorigenesis in vitro and in vivo (Figures 2 and 3).
Here we describe a mechanism in which H19 functions as a
ceRNA to sponge let-7 family of microRNAs and promotes the
expression of core pluripotency factor LIN28 (Figures 4 and 5).
Intriguingly, H19 is also repressed by let-7 in a negative-
feedback mechanism. In consequence, LIN28 can also
indirectly promote H19 expression through suppressing the
miRNA level of let-7 (Figure 6).
Emerging evidence suggests that CSCs exist in many
cancers and are closely associated with cancer progression,
metastasis and chemoresistance.10,32,33 To fully explore their
potentials as cancer markers and drug targets, a better
understanding of the underlying molecular basis of cancer
stem cell maintenance is required. As the core pluripotency
factors OCT4, SOX2 and c-Myc are regulated by lincRNAs
feedback loops,34,35 it is therefore suggested that lincRNA
may be involved in maintaining cancer stem cell phenotypes.
Consistent with this idea, suppression of H19 with siRNA in
prostate epithelial cells (RWPE-1) decreases colony-forming
potential. Conversely, overexpression of H19 significantly
increases sphere-forming capacity.36 H19 also promotes
soft-agar colony formation in breast cancer cells.37 Consis-
tently, our studies demonstrated that BCSC-enriched popula-
tions (i.e., ALDH1+ subpopulation, mammoshperes, 3D
culture cells and SP cells) and breast tumors displayed high
lncRNA-H19 expression. Gain or loss of function analysis
further confirmed that H19 is critical for BCSC properties
in vitro. In addition, previous study also showed that over-
expression of H19 promotes breast tumor progression after
subcutaneous injection of H19-recombined cells into SCID
mice.37 Indeed, our findings demonstrated that H19 not only
facilitates tumor growth but also elevates tumor-initiating
ability in xenograft nude mice model. However, we also found
that neither overexpression nor depletion of H19 had effect on
cell proliferation in breast cancer cells, indicating that spheroid
formation, anchorage-independent colony formation and
tumor-initiating abilities regulated by H19 are linked to self-
renewal and not proliferation.
Subcellular localization is often a useful predictor for the
function and mechanism of action of lincRNAs. For example,
nuclear lincRNAs need to be associated with chromatin-
remodeling complexes to regulate transcription, e.g.,
HOTAIR.38 In addition, cytoplasmic lincRNAs mostly function
as endogenous ‘sponges’ for miRNAs and act as post-
transcriptional regulators,39 such as LincROR.40 Recent
findings revealed that cytoplasmic H19 functions as an
endogenous sponge for the let-7 family of microRNAs to
regulate cancer metastasis41 andmusclemetabolism.42 In our
study, H19 localized in the cytoplasm is associated with AGO2
and acts to sponge let-7 to inhibit its bioactivity in breast
Figure 5 H19/let-7 axis modulates LIN28 expression and CSCs maintenance. (a) The protein levels of a panel of core pluripotency factors were evaluated in H19
overexpression MDA-MB-231 (left) or SK-BR-3 (right) cells. (b) The protein level of LIN28 were confirmed by western bolt in H19 depletion cancer cells. (c) H19 shared regulatory
let-7 miRNA with LIN28. The target validation was confirmed by using a luciferase reporter (psi-LIN28) transfected into MDA-MB-231 cells. Numbers are mean± S.D. (n= 3,
**Po0.01). (d) Psi-LIN28 was transfected into MDA-MB-231 cells, together with 0, 20, 40 and 80 ng of sponge plasmid WT H19 or Mut H19. Numbers are mean± S.D. (n= 3,
*Po0.05 and **Po0.01). (e) The protein levels of LIN28 were determined in the indicated groups 48 h post transfection. (f) Overexpression of LIN28 rescued lentivirus shH19-
mediated reduction of self-renewal in mammosphere formation assays. Numbers are mean±S.D. (n= 3, **Po0.01 and ***Po0.001). (g) Analysis of LIN28 expression in
breast cancerous tissue and adjacent normal tissues (n= 20). The relative LIN28mRNA level was normalized to ACTB. The statistical differences were analyzed using the paired
t-test. (h) The protein level of LIN28 in three pairs of randomly chosen clinical specimens was confirmed by western blot. (i) Spearman correlation showed positive correlations
between expression of H19 and LIN28 in a statistically significant manner (n= 20)
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cancer cells. Furthermore, H19 functions as a novel upstream
regulator of the core pluripotency factor LIN28 and protects
LIN28 from let-7-mediated degradation. Intriguingly, LIN28
also suppresses the production of let-7. H19 is downregulated
by its target miRNA let-7 in non-diabetic muscle,42 myotubes43
and breast cancer cells. In consequence, an accumulation
of LIN28 can indirectly elevate H19 expression through
inhibiting let-7. Thus, we identify a novel negative-feedback
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mechanism between H19 and let-7, as well as a double-
positive feedback loop between H19 and LIN28 mediated
through let-7 in breast cancer.
In general, feedback loops are widely observed between
miRNAs and their targets. They allow the regulatory network
to maintain bi-stable states.44 In a previous study, miR-489
and HER2-SHP2-MAPK signaling axis form a double-
negative feedback loop that can regulate breast cancer cell
proliferation and tumor progression.45 A double-negative
feedback loop involving ZEB2 and miR-145 has a critical role
in EMTand stemness maintenance during bone metastasis of
prostate cancer cells.46 Here we reveal that lncRNA-H19,
functioning as a ceRNA, links the network of miRNA let-7 and
core transcription factor LIN28. H19 overexpression in breast
cancer breaks the homeostatic balance between let-7 and
LIN28, leading to the inhibition of let-7 and subsequent
elevation of LIN28. Furthermore, accumulation of LIN28 not
only activates downstream signaling to promote self-renewal,
but also reciprocally increases the H19 expression. This novel
regulatory mechanism establishes a comprehensive regula-
tory network that adapts to environmental changes in the
maintenance of BCSCs. Importantly, both quality and quantity
of let-7 are dual-suppressed in double-negative feedback loop.
In addition, let-7 displays a lower expression in breast tumor
tissues compared with adjacent tissues. As let-7 miRNA is a
key tumor suppressor that targets numerous oncogenes such
as c-Myc and RAS,47,48 this double ‘beat’ for let-7 releases its
oncogenic factors and underlines BCSC maintenance.
In summary, our studies reveal that lncRNA–miRNA–mRNA
double-negative feedback loop constitutes a new dimension of
post-transcriptional gene regulation in BCSCs. H19 functions as
a ceRNA to constitute a dual-feedback regulatory circuitry with
let-7 and LIN28. This bi-directional regulation network reflects a
novel mechanism with a vital role in BCSC maintenance.
Targeting this newly identified regulatory circuitry provides
therapeutic opportunities for aggressive breast cancers.
Materials and Methods
Clinical samples, cell lines and primary breast cancer cell
isolation. All breast cancer samples were obtained from newly diagnosed
patients with prior patients consent and the approval of the Institutional Clinical
Ethics Review Board of the first Affiliated Hospital of Dalian Medical University.
Samples were frozen in liquid nitrogen for mRNA and protein extraction. Overall
survival was defined as the period from the date of diagnosis to the date of death.
Human breast cancer cell lines MDA-MB-231, SK-BR-3 and MCF-7 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA),
respectively. BT-549 cells were maintained in RPMI-1640 (Invitrogen) supplemented
with 10% fetal bovine serum. MCF-10A cells were cultured in DMEM/F12 medium
(Invitrogen) supplemented with 5% horse serum (HyClone, Logan, UT, USA), 20 ng/
ml EGF (Sigma-Aldrich, St Louis, MO, USA), 100 ng/ml cholera toxin (Sigma-
Aldrich), 100 ng/ml insulin (Sigma-Aldrich) and 500 ng/ml hydrocortisone (Sigma-
Aldrich). HEK293T cells were routinely cultured in DMEM medium supplemented
with 10% fetal bovine serum. All cells were incubated at 37 °C in a humidified
incubator containing 5% CO2. All cell lines were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA). The cell lines were authenticated at
American Type Culture Collection before purchase by their standard short tandem
repeat DNA typing methodology. For primary breast cancer cell isolation, the tumor
xenografts were mechanically and enzymatically dissociated to yield clumps of
epithelial cells by incubation at 37 °C for 2 h in a 1:1 solution of collagenase I (3 mg/
ml): hyaluronidase (100 U/ml; Sigma-Aldrich). After filtration through a 40 μm pore
filter and washing with PBS, the tumor tissues were trypsin dissociated to single
cells for subsequent experiments.
Fluorescence-activated cell sorting. For ALDH1 assay, the ALDH1+
population was detected by ALDEFLUOR kit (Shanghai Stem Cell Technology Co.
Ltd, Shanghai, China) following manufacturer instructions. MDA-MB-231 cells
(1 × 106 per ml) were analyzed on a BD FACScalibur flow cytometer (BD
Biosciences, Franklin Lakes, NJ, USA) after staining in ALDH1 substrate containing
assay buffer for 30 min at 37 °C. The negative control was treated with
diethylaminobenzaldehyde, a specifc ALDH1 inhibitor. ALDH1+ or ALDH1− cells
(at least 1 × 106) were collected for RNA extraction. For SP cells sorting, MDA-
MB-231 cells (1 × 106 per ml) were incubated with 2 μm FTC, an ABCG2-specifc
inhibitor, for 20 min in negative control tubes before adding Hoechst 33342 (Sigma-
Aldrich). Then, MDA-MB-231 cells were incubated in Hanks’ balanced salt solutions
supplemented with 2% FBS, 10 mM HEPES, 5 μg/ml Hoechst 33342 for 90 min at
37 °C with mixing every 15 min, followed by washing with cold growth medium.
Cells were resuspended at a concentration of 2 × 106 per ml. Then, PI was added to
a final concentration of 2 μg/ml to discriminate dead cells from live cells. The gating
of side population was based on negative controls in which FTC was used. Finally,
cells were analyzed on a BD FACScalibur flow cytometer and collected at least
1 × 106 SP cells or non-SP cells for RNA extraction.
Fluorescent in situ hybridization. A fragment of H19 designed as its
probe was used and labeled with digoxigenin (DIG)-UTP (Roche, Mannheim,
Germany) using the mMESSAGE T7 Ultra In Vitro Transcription kit (Ambion, Austin,
TX, USA) in accordance with the manufacturer’s directions. Slides were hybridized
with probes overnight, washed twice with 50% formamide/2 × saline sodium citrate
(SSC) and twice with 2 × SSC at 50 °C for 5 min each, then incubated with 1:500
diluted sheep anti-Dig (lnvitrogen) for 1 h at 37 °C, followed by counterstained with
DAPI (1 μg/ml), visualized using a confocal microscope (Leica, Wetzlar, Germany).
Probe sequences were listed in Supplementary Table 1.
Plasmids construction and stable cell lines generation. Flag-LIN28
was built as described by Qiu et al.49 Wild-type human H19 (WT H19) and mutant
human H19 (Mut H19) were constructed as previously described.43 psiCHECK2-
H19 and psiCHECK2-H19D with or without two copies of predicted that let-7-binding
sites were established as described by Kallen et al,43 psiCHECK2-let7 4 × was built
as described by Iwasaki et al.50 To make psiCHECK2-LIN28, the bioinformatics tool
Miranda (http://www.microrna.org) was used to search for let-7-binding sites in the
full-length transcripts of LIN28 and predicted let-7-binding sites within LIN28 3′-UTR
fragments were obtained by RT-PCR and were inserted into the luciferase reporter
vector psiCHECK2 (Promega, Madison, WI, USA) between Xho1 and Not1 sites.
H19 and LIN28 cloned from WT H19 and Flag-LIN28 were inserted in pLVX-DsRed-
N1-Monomer (Clontech, Mountain View, CA, USA) between BamH1 and Not1 sites
to construct pLVX-H19-DsRed and pLVX-LIN28-DsRed. The pLVX-H19-DsRed and
Figure 6 LncRNA-H19 formed a double-negative circuitry with miR-let-7 and LIN28 in breast cancer cells. (a) MDA-MB-231 cells were transfected with LIN28-overexpressing
vector (LIN28) or empty vector (EV), the protein level of LIN28 was quantified by western blot 72 h post transfection. (b) The relative H19 mRNA level was analyzed by RT-qPCR
when overexpressed LIN28. Numbers are mean± S.D. (n= 3, ***Po0.001). (c) The protein level of LIN28 was detected 72 h after transfection of siRNAs targeting LIN28
(siLIN28) or siNC. (d) LIN28 depletion decreased expression of H19. Numbers are mean±S.D. (n= 3, **Po0.01 and ***Po0.001). (e) LIN28-overexpressing vector (LIN28) or
empty vector (EV) was transfected into MDA-MB-231 cells. After transfection 48 hours, let7a/7b miRNA levels were measured by RT-qPCR. Numbers are mean ± SD (n = 3,
**Po0.01). (f) MDA-MB-231 cells were transfected with 48 nM control miRNA (NC), let-7 mimics (mlet-7) or let-7 inhibitors (ilet-7). RNAs were extracted 48 h later and RT-qPCR
analysis performed. Numbers are mean±S.D. (n= 3, **Po0.01 and ***Po0.001). (g) MDA-MB-231 cells were transfected with the indicated mixture, and the relative H19
mRNA level was detected by RT-qPCR. Numbers are mean±S.D. (n= 3, *Po0.05). (h and i) Let-7a (h) or let-7b (i) miRNA levels in clinical specimens were assessed by RT-
qPCR. Numbers are mean±S.D. (n= 3, **Po0.01 and ***Po0.001). (j) Model for the H19/let7/LIN28 regulatory loop in the modulation of BCSCs maintenance
H19/let-7/LIN28 feedback loop maintains BCSCs
F Peng et al
11
Cell Death and Disease
pLVX-LIN28-DsRed lentivirus were packaged in HEK293T cells and viral particles
were collected 48 h post transfection. After infection, the cells stably expressing H19
and LIN28 were chosen by selection with 2 μg/ml puromycin (Sigma-Aldrich),
respectively. For shRNA lentiviruses (GenePharma, Suzhou, China) infection, cells
were infected in six-well plates and subsequently split into 10 cm dishes in the
presence of 2 μg/ml puromycin for selection over 72 h. All primer sequences were
listed in supplementary table 1.
siRNAs, microRNA mimics and microRNA inhibitors transfec-
tion. Transient transfection was performed by using Lipofectamine 2000
(Invitrogen) according to the manufacturersection, cel. The following reagents were
used: siRNAs specifically targeting H19, LIN28 and siRNA control were purchased
from GenePharma, and miR-let7a or miR-let7b mimics, Pre-miR negative control,
miR-let7a or miR-let7b inhibitors and anti-miR control were purchased from Qiagen,
Valencia, CA, USA (let-7a, cat. no. MS00006482, let-7b, cat. no. MS00003122). All
primer sequences were listed in Supplementary Table 1.
Mouse mammary tumor model and xenograft tumor formation.
Mice carrying the beta-lactoglobulin Cre (BLG-Cre) transgene, homozygous for floxed
exons 22–24 of the breast cancer 1 (Brca1) allele, and heterozygous for p53 tumor
suppressor gene (Trp53) deficiency were bred (The Jackson Laboratory, Mouse strain
datasheet-012620, Bar Harbor, ME, USA). After two rounds of pregnancy, tumors were
allowed to grow and used for subsequent experiments. For xenograft model, MDA-
MB-231-shCtrl or MDA-MB-231-shH19 cells (6 × 106) in 100 μl matrigel were
subcutaneously injected at the right or left dorsal fank of female nude mice (4–
6 weeks), respectively. The body weight of the animals and the two perpendicular
diameters (a and b) were recorded every 3 days. Tumor volume (V) was calculated
according to the following formula: V= (a × b × b)/2. After 6 weeks, tumor mass was
resected and dissociated to form tumor suspension for the secondary serial tumor
transplantation. The protocol was performed as previous described. Then, 1 × 105,
1 × 104, 1 × 103 and 1 × 102 tumor cells isolated from the first tumor xenografts were
injected into nude mice. Subsequent steps were similar with the first tumor
transplantation. Investigation was conducted in accordance with the ethical standards
and according to the Declaration of Helsinki and national and international guidelines
approved by the institutional animal care and use committee of Dalian Medical University.
Luciferase reporter assay. MDA-MB-231 cells (1 × 104) were seeded into
each well of 48-well-plate and the following steps were carried out as previously
described.49 MDA-MB-231 cells were co-transfected with 10 ng of the indicated
luciferase reporter and 48 nM miRNA mimics (Qiagen, Valencia, CA, USA) using
Lipofectamine 2000 (Invitrogen). Eighteen hours after transfection, luciferase activity
was monitored using the Dual-Luciferase Reporter Assay System (Promega) and a
luminometer (Molecular Devices, Sunnyvale, CA, USA). Renilla luciferase activity
was normalized against firefly luciferase activities and presented as percentage of
inhibition. Results represented the average of triplicate samples from three
independent experiments.
Immunoprecipitation assay. The RIP experiment was carried out as
previously described43 using rabbit anti-AGO2 antibody (Abcam, Cambridge, MA,
USA) on extracts of breast cancer cells MDA-MB-231. The co-precipitated RNAs
were extracted with Trizol reagent (Invitrogen) and detected by RT-qPCR. The
specificity of the AGO2 antibody was confirmed by immunoprecipitation (IP). MDA-
MB-231 cells (1 × 107) were lysed in the soft lysis buffer. Rabbit anti-AGO2 antibody
(2 μg)- or control IgG (2 μg)-coated magnetic beads was added to each binding
reaction tube and incubated at 4 °C for 4 h. Beads were washed five times with the
washing buffer and boiled in the loading buffer for 10 min. The proteins were
subjected to SDS-PAGE and detected by mouse anti-AGO2 antibody (Millipore,
Billerica, MA, USA).
For 3D culture, sphere cells culture, transwell migration assay, cell plate colony
formation assay, sphere formation assay, RNA extraction RT-PCR and real-time PCR
analysis, western blot assay, proliferation assay and statistical analysis, see
Supplementary Materials and Methods.
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